Rakuten doses first patients in multi-continental Phase III HNSCC trial
The trial builds off the company’s previous Phase Ia/II trial that saw an estimated survival rate of 52.4% at 24 months in HNSCC patients.
24 January 2025
24 January 2025
The trial builds off the company’s previous Phase Ia/II trial that saw an estimated survival rate of 52.4% at 24 months in HNSCC patients.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.